List view / Grid view
In this whitepaper, IntelliCyt Corporation describe how the iQue Screener is used to perform multiplexed screens for antibody binding to either cell surface or to circulating target antigens...
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
This application note illustrates the value of multiplexing, rapid sampling, and assay miniaturisation using QBeads on the iQue Screener...
In this application note, IntelliCyt Corporation demonstrate a fast, efficient, radioactivity-free CMC assay with low sample input requirements, enabling miniaturisation to 384-well plates, using the iQue® Screener...
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium...
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
24 March 2017 | By IntelliCyt
The fastest way to the best clones...
Dr Sheraz Gul, Head of Assay Development and Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology, answers questions on assay procedures...
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
Two-dimensional monolayer cell proliferation assays for cancer drug discovery have enabled large-scale screens. But they represent a simplified view of oncogenes or tumour suppressor genes as the genetic drivers of cancer cell proliferation.
